Pfizer (NYSE:PFE) Given New $30.00 Price Target at JPMorgan Chase & Co.

Pfizer (NYSE:PFE) had its price target raised by JPMorgan Chase & Co. from $28.00 to $30.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 6.15% from the stock’s previous close.

A number of other analysts also recently commented on the company. HSBC upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Scotiabank upped their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday. BMO Capital Markets cut their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.72.

Pfizer Trading Up 1.6%

Shares of PFE traded up $0.44 during mid-day trading on Friday, hitting $28.26. The company had a trading volume of 16,169,450 shares, compared to its average volume of 40,429,355. Pfizer has a 1-year low of $23.62 and a 1-year high of $29.21. The business’s 50-day simple moving average is $27.62 and its 200-day simple moving average is $26.49. The stock has a market cap of $161.08 billion, a PE ratio of 37.17, a P/E/G ratio of 1.88 and a beta of 0.32. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer will post 2.98 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Riversedge Advisors LLC increased its holdings in Pfizer by 153.1% in the third quarter. Riversedge Advisors LLC now owns 28,400 shares of the biopharmaceutical company’s stock valued at $810,000 after buying an additional 17,180 shares during the last quarter. Wedmont Private Capital lifted its holdings in Pfizer by 138.1% during the 3rd quarter. Wedmont Private Capital now owns 99,498 shares of the biopharmaceutical company’s stock worth $2,768,000 after buying an additional 57,713 shares during the last quarter. Werlinich Asset Management LLC grew its position in shares of Pfizer by 0.4% in the 3rd quarter. Werlinich Asset Management LLC now owns 92,600 shares of the biopharmaceutical company’s stock worth $2,641,000 after acquiring an additional 400 shares in the last quarter. Journey Retirement Planning & Investment Management LLC bought a new stake in shares of Pfizer in the 3rd quarter valued at approximately $222,000. Finally, WoodTrust Financial Corp raised its position in shares of Pfizer by 0.3% during the 3rd quarter. WoodTrust Financial Corp now owns 418,180 shares of the biopharmaceutical company’s stock valued at $11,927,000 after acquiring an additional 1,294 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for patients with HER2-positive metastatic breast cancer. The expanded label moves TUKYSA into an earlier stage of care, potentially broadening its addressable market and supporting Pfizer’s oncology-growth strategy. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Jefferies initiated or reiterated a Buy rating on Pfizer, while Cantor Fitzgerald raised its price target to $28, providing additional support for the stock’s valuation narrative. A separate analysis also upgraded Pfizer to a cautious bullish view. Pfizer Receives a Buy from Jefferies
• Positive Sentiment: Investors continue to view Pfizer as a potential value play because of its low forward earnings multiple, substantial cash-generation capacity and dividend yield. The company’s oncology pipeline, including TUKYSA and the advancing Phase 3 tilrekimig asthma program, may help offset pressure from slower legacy-product growth. Pfizer’s Tilrekimig Phase 3 Trial
• Neutral Sentiment: Pfizer’s next earnings report is a key catalyst. Analysts expect oncology sales, biosimilars, pipeline progress and the company’s ability to deliver another earnings beat to determine whether the valuation discount is justified.
• Negative Sentiment: Pfizer’s dividend yield above 6% is drawing scrutiny because it may reflect a depressed share price and investor concerns about earnings, cash flow, debt and payout sustainability. Commentators warn that a frozen dividend and prior write-downs make the high yield less reassuring than it appears. Pfizer’s Dividend Yield Is Above 6%
• Negative Sentiment: Pfizer plans to close a penicillin unit in Italy and eliminate approximately 330 jobs. The restructuring could improve efficiency, but it also highlights ongoing pressure to reduce costs amid sluggish revenue growth, thin margins and concerns about returns on equity.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.